Ig NextGen 10% in Patients With Primary Immune Deficiency (PID)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2007
This study aims to assess the safety, tolerability and pharmacokinetics of Ig NextGen 10% in patients with primary immune deficiency currently being treated with Intragam P. Eligible patients will switch from 3 to 4 weekly intravenous Intragam P therapy to receive seven cycles of Ig NextGen 10% treatment administered intravenously at three- to four-weekly intervals. Patients will be monitored on the study for up to 36 weeks.
Epistemonikos ID: 6ccfd834c5e86d79a126569dfbfa79040f5a7c1d
First added on: May 04, 2024